Covista is a cash-generative healthcare education compounder, benefiting from structural clinician shortages, scalable enrollment growth, and disciplined capital returns, but carrying meaningful federal student-aid regulatory risk.
Covista Inc. (CVSA), formerly known as Adtalem Global Education Inc. and historically DeVry Education Group, operates as a leading for-profit higher education corporation based in Chicago, Illinois.[1, 2, 3] The company rebranded to Covista in February 2026 to align its identity with its core strategic mission as the nation’s largest private healthcare educator.[1, 2, 3, 4] Covista addresses critical domestic workforce shortages across healthcare, veterinary medicine, clinical psychology, and educational sectors through its portfolio of five accredited, specialized post-secondary institutions.[5, 6] The operational platform spans both physical campus networks and scalable, tech-enabled online learning modalities.[2, 5, 7]
The company generates revenues through student tuition and related academic fees, structured under three core segments: Chamberlain, Walden, and Medical and Veterinary.[8] Historically, tuition is collected upfront, creating a strong working capital model.[9] This mechanism is reflected in a high level of deferred revenue, which stood at $276.2 million as of March 31, 2026, compared to $214.1 million as of June 30, 2025.[9] While the vast majority of its enrolled customer base is located in the United States, pre-clinical instruction for the medical and veterinary programs is delivered at physical campuses in the Caribbean, specifically Barbados, Sint Maarten, and St. Kitts, with clinical rotations subsequently integrated within an extensive network of affiliate hospitals throughout the United States.[1, 6, 10]
| Segment Name | Core Institutional Brands | Primary Program Offerings | Revenue Model & Scale |
|---|---|---|---|
| Chamberlain | Chamberlain University [6] | Pre-licensure Bachelor of Science in Nursing (BSN), Master of Science in Nursing (MSN), and Doctor of Nursing Practice (DNP) [7, 8] | Underpinned by physical campus locations and hybrid delivery, currently serving 40,767 students [8] |
| Walden | Walden University [6] | Online doctoral, postgraduate, and undergraduate degrees in nursing, social work, counseling, behavioral sciences, and education [8, 11, 12] | Fully remote, highly scalable online instruction model serving 54,474 students [8] |
| Medical and Veterinary | American University of the Caribbean (AUC) School of Medicine, Ross University School of Medicine (RUSM), Ross University School of Veterinary Medicine (RUSVM) [1, 6] | Doctor of Medicine (MD) and Doctor of Veterinary Medicine (DVM) professional degrees [1, 8] | Caribbean-based pre-clinical instruction coupled with standardized clinical rotations in U.S. affiliate networks, serving 5,344 students [8, 10] |
The primary customer types are non-traditional adult learners, practicing nurses seeking post-licensure specialization, and aspiring medical and veterinary professionals.[7, 13] These students select Covista's institutions over public and non-profit alternatives due to several structural factors. First, public universities operate under strict enrollment caps and faculty limitations, leaving tens of thousands of qualified applicants turned away annually.[14] Second, the "Chamberlain Care" model provides high-touch student support and adaptive tutoring designed to improve student persistence and licensure pass rates.[7, 15] Finally, the flexibility of Walden’s online programs allows working professionals to complete advanced degrees without disrupting their current employment.[5, 7]
Covista’s financial results are driven by total enrollment growth, program-specific tuition adjustments, retention rates, and active capacity expansions.[8, 11] The next phase of expansion is governed by its next three-year growth plan, "Purpose at Scale," which commences in fiscal year 2027 and targets a student enrollment base exceeding 120,000 by fiscal year 2029.[2, 13, 16] This strategy builds upon the operational discipline of the previous "Growth with Purpose" phase, transforming the company from an education provider into a comprehensive talent platform integrated with major hospital systems and employers nationwide.[16, 17]
To drive organic enrollment growth, Chamberlain University is executing a physical campus expansion program. The university plans to open its 25th campus in Cincinnati, Ohio, for the Fall 2026 semester to address regional nurse shortages.[18] Under the "Purpose at Scale" strategy, management plans to invest in ten to fifteen new Chamberlain campuses by 2029.[13] Each site is projected to achieve positive EBITDA within two years of operation, with capital payback completed in three to five years.[13] On the online front, Walden University leverages its fast-to-market program development capabilities to capture shifting clinical demands.[11] Walden recently secured approvals to launch seven new programs, including specialized Bachelor of Science tracks in Special Education and Palliative Care, which are entering immediate enrollment cycles.[8, 11]
"PURPOSE AT SCALE" (FY27-FY29)
│
┌────────────────────────┼────────────────────────┐
▼ ▼ ▼
Campus Expansion Employer Pipelines AI & Tech Innovation
• 10-15 new BSN sites • Contracted B2B models • Google Cloud classroom
• EBITDA positive <2yr • Direct hospital hiring • Certified AI credentials
The economic moat protecting Covista is structural, consisting of an extensive clinical placement network, significant regulatory barriers, and platform scale advantages.[7, 19] First, healthcare students cannot graduate or obtain licensure without completing mandatory clinical hours.[19] Covista possesses over 3,200 contracted clinical partner sites across the United States.[7] This network represents a massive asset that traditional public or online-only universities cannot easily replicate, as securing new clinical affiliations is a highly localized and zero-sum process.[7, 19] Second, the regulatory hurdles to gain programmatic approvals from state boards of nursing and regional accreditors are high.[19, 20] The years required to navigate probationary audits, clinical site validation, and curriculum compliance create a strong barrier to entry.[19, 20] Finally, the non-transferability of credits between professional medical and nursing programs creates high switching costs, locking in student tuition once clinical tracks begin.[19]
The total addressable market (TAM) is large, growing, and driven by secular tailwinds.[19, 20] The United States faces a critical, compounding shortage of healthcare professionals, with an estimated deficit of over one million registered nurses by 2030 and a physician shortage of 37,000 by 2037.[5] The market for domestic nursing education is valued in the tens of billions of dollars, expanding at a steady CAGR of 6% to 8%.[19] The allied health and training market is highly fragmented, growing at 5% to 7% annually as clinical settings shift toward outpatient clinics and urgent care facilities.[19, 21]
| Competitor Name | Primary Segment | Enrollment Base (Approximate) | Strategic Positioning vs. Covista |
|---|---|---|---|
| Strategic Education Inc. (Capella / Strayer) [7] | Online Professional [7] | ~120,000 active learners [7] | Competes directly with Walden University in postgraduate nursing and business programs; lacks Covista's physical, pre-licensure BSN campus model.[7] |
| Grand Canyon Education (LOPE) [7] | Hybrid and BSN [7] | Large-scale hybrid footprint [7] | Strong competitor in physical nursing programs; matches Chamberlain's geographic reach but has less depth in international medical and veterinary programs.[7] |
| Caribbean Medical Competitors (St. George's) [7] | Medical Education [7] | Regional Caribbean cohorts [7] | Competes with Ross University and AUC for clinical rotations and U.S. residency spots; Covista has greater platform diversification.[7] |
| Non-Profit Online Universities (SNHU / ASU) [7] | Online Undergraduate [7] | Massive scale online [7] | Put pricing pressure on general education tracks, which increases student acquisition costs in online programs.[7] |
Covista is holding and gaining ground in critical segments, particularly in pre-licensure nursing, where Chamberlain has returned to positive total enrollment growth ahead of internal forecasts.[8, 11] The school achieved its 15th consecutive quarter of pre-licensure BSN enrollment growth in the third quarter of fiscal year 2026.[8] While general online education sectors face headwinds, Walden achieved a record-high student enrollment of 54,474 (+12.3% year-over-year).[8] This enrollment trend demonstrates the resilience of Covista's vocational focus.[18]
Covista reported its fiscal third-quarter results for the period ended March 31, 2026, on May 7, 2026.[1, 5, 8] Total enrollment surpassed 100,000 students for the first time in institutional history, driven by growth across all segments.[8, 17]
Quarterly revenue was $487.0 million, a 4.5% increase year-over-year.[8] This result beat the Zacks Consensus Estimate of $478.0 million by 1.9% and Yahoo/Google Finance analyst expectations of $474.02 million by 2.74%.[1, 22] This revenue performance is particularly strong considering a one-week academic calendar timing shift at Walden University, which moved one week of revenue recognition into the second quarter of fiscal year 2026.[17] Excluding this shift, organic revenue growth for the quarter reached 8.4%.[8, 17]
The company reported GAAP operating income of $91.3 million, up from $90.5 million in the prior year period.[8] Adjusted operating income was $102.2 million.[8, 23] Excluding the Walden timing shift, adjusted operating income would have increased by 14.1% year-over-year to $120.3 million, reflecting strong operational leverage.[23] Adjusted EBITDA reached $127.9 million, compared with $127.8 million in the prior year, with adjusted EBITDA margin reported at 26.3% compared to 27.4% in the prior year.[8] Excluding the calendar shift, adjusted EBITDA would have reached $145.9 million, expanding adjusted EBITDA margin by 150 basis points to 27.8%.[17]
GAAP net income was $41.6 million, down from $60.8 million in the prior year.[8] This decrease was driven by a loss in discontinued operations.[8, 9] Net income from continuing operations was $58.0 million.[8, 9] Adjusted net income was $69.0 million, compared with $73.3 million in the prior year.[8] Diluted GAAP EPS was $1.20 compared to $1.59.[8] Adjusted EPS reached $1.98, representing a 3.1% increase year-over-year and beating consensus analyst expectations of $1.72–$1.73 by 14.5% to 14.95%.[1, 8, 22]
| Financial Metric | Q3 FY2026 | Q3 FY2025 | Reported Change | Change (Shift-Adjusted) |
|---|---|---|---|---|
| Total Student Enrollment | 100,585 [8] | 94,181 | +6.8% [8, 17] | +6.8% [8] |
| Quarterly Revenue | $487.0M [8] | $466.1M [24] | +4.5% [8] | +8.4% [8, 17] |
| GAAP Operating Income | $91.3M [8] | $90.5M [8] | +0.9% [8] | +14.1% [23] |
| Adjusted EBITDA | $127.9M [8] | $127.8M [8] | +0.1% [8] | +14.2% [17, 23] |
| Adjusted EBITDA Margin | 26.3% [8] | 27.4% [8] | -110 bps [8] | +150 bps [17] |
| GAAP Net Income | $41.6M [8] | $60.8M [8] | -31.6% [8] | — |
| Adjusted EPS | $1.98 [8] | $1.92 [8] | +3.1% [8] | ~14.0% [17] |
For the first nine months of fiscal year 2026, Covista generated strong operating cash flow of $346.5 million.[9] Free cash flow for the trailing twelve months reached $336.5 million, up from $287.2 million in the prior year.[22, 25] The company completed a debt refinancing in March 2026, issuing a new $510.0 million Term Loan B due in March 2033 to repay $405.0 million of outstanding 5.50% Senior Secured Notes due in 2028.[9] This action extended the company's debt maturity profile and maintained a low leverage position, with net leverage reported at 0.7x as of March 31, 2026.[8, 9]
Following the earnings beat, management raised its fiscal year 2026 guidance:
* Revenue Guidance: Raised to a range of $1,930 million to $1,945 million (representing 8% to 9% growth year-over-year), up from the previous range of $1,900 million to $1,940 million.[8, 17]
* Adjusted EPS Guidance: Raised to a range of $7.95 to $8.15 (representing 19% to 22% growth year-over-year), up from the previous range of $7.80 to $8.00.[8, 17]
The earnings announcement positively impacted analyst sentiment and price targets.[26] Consensus price targets increased by 12% from $143 to an average of $156.25 (with high targets reaching $175 and lowest at $140).[1, 18] Post-announcement, the stock maintained strong upward momentum, gaining nearly 25% over the following 90 days to peak above $131 per share in early June 2026.[27]
However, in mid-June 2026, a hawkish policy announcement from new Federal Reserve Chair Kevin Warsh triggered a market-wide correction.[27] This correction, combined with executive profit-taking, caused Covista's share price to pull back to $119.07 as of June 18, 2026.[27, 28]
For-profit educational institutions are valued based on cash flow predictability and capital return efficiency.[7, 26] Key underlying drivers for Covista's valuation include:
* Five-Year Sales Growth Profile: Sustained revenue expansion is driven by the physical expansion of Chamberlain University (projecting 10 to 15 new campuses by 2029) and Walden's programmatic launches.[8, 13]
* Long-Term Revenue Trend: The historical sales growth trajectory outlines a steady recovery post-divestitures [15]:
| Fiscal Year End | Annual Revenue | YoY Revenue Growth | Key Drivers and Corporate Actions |
|---|---|---|---|
| June 30, 2021 | $899.3M [29] | +3.8% [24, 29] | Core focus on medical, veterinary, and nursing tracks [3] |
| June 30, 2022 | $1,382.0M [30] | +53.7% [24, 29] | Financial integration of the $1.48B Walden University online acquisition [15] |
| June 30, 2023 | $1,451.0M [30] | +5.0% [24, 29] | Expansion of physical clinical networks [7] |
| June 30, 2024 | $1,585.0M [30] | +9.2% [24, 29] | Launch of the "Growth with Purpose" strategic phase [15, 17] |
| June 30, 2025 | $1,788.0M [30] | +12.9% [24, 29] | Double-digit enrollment growth at Walden (+15%) and Chamberlain (+5.8%) [31] |
Covista's physical expansion strategy involves high capital commitments.[13] Building physical Chamberlain campuses requires significant upfront capital for facilities, simulation labs, and faculty hiring.[13, 15, 33] If local student recruitment falls short of expectations, these facilities will act as an operating drag, eroding the segment's 29.7% margins.[8, 17]
Additionally, student acquisition costs (CAC) are rising across online channels, which could pressure Walden’s marketing ROI.[7, 31]
The online post-secondary market is highly competitive and pricing-sensitive.[7] Traditional non-profit public universities are expanding low-cost online degree programs, which could slow Walden’s enrollment momentum.[7]
Covista is exposed to regulatory changes in federal student aid.[7, 34] Since 2016, the company has received over $11.3 billion in federal student loan disbursements under Title IV.[34] Any policy changes that restrict access to these funds would directly impact student enrollments.[10, 34]
COMPLIANCE & REGULATORY THREATS
│
┌──────────────────────────┼──────────────────────────┐
▼ ▼ ▼
Gainful Employment Borrower Defense Provisional Status
• Debt-to-income audits • Recoupment liabilities • Expired Title IV agreements
• 50% Walden programs at risk • Class-action settlements • Letter-of-credit risk
While net leverage of 0.7x is conservative, the newly refinanced $510.0 million Term Loan B exposes the company's cost structure to high interest rates.[8, 9]
The 5-year scenario model projects Covista’s financial path through fiscal year 2031, using a current base share price of $119.07.[28]
The projected share price trajectory shows the expected value path for each scenario over the next five years:
| Scenario / Year | Year 0 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|---|
| High Case (USD) | $119.07 | $141.00 | $169.00 | $202.00 | $241.00 | $284.76 |
| Base Case (USD) | $119.07 | $129.00 | $140.00 | $152.00 | $166.00 | $181.05 |
| Low Case (USD) | $119.07 | $112.00 | $105.00 | $99.00 | $94.00 | $89.21 |
The probability-weighted target price is calculated as:
$\text{Projected Price Target} = (0.20 \times \$284.76) + (0.55 \times \$181.05) + (0.25 \times \$89.21) = \$56.95 + \$99.58 + \$22.30 = \$178.83\text{ USD}$
This probability-weighted target price of $178.83 USD implies a 50.2% total return over the 5-year investment horizon.
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $3,054M Revenue [13] | 14.5% Net Margin / $15.82 EPS [19] | 18.0x P/E [1] | $119.07 [28] | $284.76 USD [1] | 139.2% | 19.1% | 20.0% |
| Base Case | $2,785M Revenue [4] | 13.0% Net Margin / $12.07 EPS [36] | 15.0x P/E [37] | $119.07 [28] | $181.05 USD [37] | 52.1% | 8.7% | 55.0% |
| Low Case | $2,360M Revenue [34] | 11.0% Net Margin / $8.11 EPS [34] | 11.0x P/E [34] | $119.07 [28] | $89.21 USD [34] | -25.1% | -5.6% | 25.0% |
COMPOUNDING CASH FLOWS
This qualitative evaluation assesses Covista's operational, financial, and strategic positioning:
The blended qualitative score is 8.1 / 10.
SECULAR SECTOR LEADER
Covista Inc. presents a resilient, cash-generative business model positioned directly at the intersection of private professional education and systemic healthcare staffing shortages.[5, 7, 26]
INVESTMENT THESIS VECTORS
│
┌────────────────────────┼────────────────────────┐
▼ ▼ ▼
Market Leader Operational Leverage Capital Returns
• Nation's largest • Pre-licensure growth • Conservative leverage
healthcare educator at Chamberlain (0.7x net debt/EBITDA)
• 3,200+ partner sites • Scalable Walden model • Active share buybacks
Regulatory risk remains the primary structural concern.[18] Investors must monitor Gainful Employment audits at Walden, provisional Title IV status certifications, and changes to the federal Graduate PLUS loan program.[14, 34]
While regulatory risks warrant a moderate risk premium [18], the company's strong balance sheet, high free cash flow conversion, and active share buyback program suggest the stock is undervalued at current trading levels.[8, 23, 37]
STABLE VALUE COMPOUNDER
Covista's share price of $119.07 trades below its 200-day moving average of $124.96 and its 50-day moving average of $127.60, following a mid-June market pullback driven by hawkish Federal Reserve commentary.[27, 28, 41] Short-term technical indicators show the stock is in deeply oversold territory, with a 14-day Relative Strength Index (RSI) of 23.3 suggesting a potential near-term price reversal.[41] Support is established near the fifty-two-week low of $86.97, and the oversold indicators suggest a technical rebound is likely as long-term buyers react to the company's solid fundamentals.[27, 28]
OVERSOLD TECHNICAL RECOVERY
View Covista Inc. (CVSA) stock page
Loading the interactive version of this report…